Quantcast
Roche says U.S. FDA grants priority review to Actemra for COVID-19 – Metro US

Roche says U.S. FDA grants priority review to Actemra for COVID-19

FILE PHOTO: FILE PHOTO: Logo of Swiss pharmaceutical company Roche
FILE PHOTO: FILE PHOTO: Logo of Swiss pharmaceutical company Roche is pictured in Rotkreuz

ZURICH (Reuters) – Roche said on Monday the U.S. Food and Drug administration granted priority review to its Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults.

“If approved, Actemra/RoActemra would be the first U.S. FDA-approved immunomodulator for the treatment of COVID-19 in hospitalised patients,” Roche said in a statement, adding that more than 1 million people hospitalised with COVID-19 had been treated with Actemra/RoActemra worldwide since the beginning of the pandemic.

(Reporting by Silke Koltrowitz, Editing by Miranda Murray)

More from our Sister Sites